Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.

Journal of Alzheimer's Disease : JAD
Maya Arvidsson RådestigSilke Kern

Abstract

We have previously shown that older adults with preclinical Alzheimer's disease (AD) pathology in cerebrospinal fluid (CSF) had slightly worse performance in Mini-Mental State Examination (MMSE) than participants without preclinical AD pathology. We therefore aimed to compare performance on neurocognitive tests in a population-based sample of 70-year-olds with and without CSF AD pathology. The sample was derived from the population-based Gothenburg H70 Birth Cohort Studies in Sweden. Participants (n = 316, 70 years old) underwent comprehensive cognitive examinations, and CSF Aβ-42, Aβ-40, T-tau, and P-tau concentrations were measured. Participants were classified according to the ATN system, and according to their Clinical Dementia Rating (CDR) score. Cognitive performance was examined in the CSF amyloid, tau, and neurodegeneration (ATN) categories. Among participants with CDR 0 (n = 259), those with amyloid (A+) and/or tau pathology (T+, N+) showed similar performance on most cognitive tests compared to participants with A-T-N-. Participants with A-T-N+ performed worse in memory (Supra span (p = 0.003), object Delayed (p = 0.042) and Immediate recall (p = 0.033)). Among participants with CDR 0.5 (n = 57), those with amyloid pa...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Dec 1, 1995·Molecular and Chemical Neuropathology·K BlennowE Vanmechelen
May 7, 2002·The Clinical Neuropsychologist·Jane H CerhanBradley F Boeve
Jan 21, 2004·Archives of Neurology·Michael GrundmanUNKNOWN Alzheimer's Disease Cooperative Study
Jun 5, 2004·Neuropsychologia·Julie D HenryLouise H Phillips
Mar 19, 2005·Brain : a Journal of Neurology·Hélène AmievaJean-François Dartigues
Aug 1, 2006·Lancet·Kaj BlennowHenrik Zetterberg
Nov 13, 2008·Archives of Neurology·Howard Jay AizensteinWilliam E Klunk
Dec 2, 2008·Brain : a Journal of Neurology·E C MorminoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Dec 11, 2008·Annals of Neurology·Hélène AmievaJean François Dartigues
Apr 3, 2009·Journal of Neuropsychology·Jane A LonieKlaus P Ebmeier
Feb 1, 2011·Annals of Neurology·Victor L VillemagneChristopher C Rowe
Jun 22, 2011·Neuropsychologia·Dorene M RentzReisa A Sperling
Sep 25, 2012·Journal of Alzheimer's Disease : JAD·Yen Ying LimPaul Maruff
Jun 12, 2013·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Edmond TengPo H Lu
Sep 10, 2013·Lancet Neurology·Stephanie Jb VosAnne M Fagan
Sep 21, 2013·Neurology·Argonde C van HartenWiesje M van der Flier
Mar 13, 2014·Molecular Psychiatry·P M DoraiswamyUNKNOWN AV45-A11 Study Group
Jun 19, 2016·Neurobiology of Aging·Stephanie J B VosTammie L S Benzinger
Dec 16, 2016·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·Valgeir ThorvaldssonBoo Johansson
Aug 21, 2018·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Maria VassilakiRosebud O Roberts
Nov 14, 2018·European Journal of Epidemiology·Therese Rydberg SternerIngmar Skoog

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.